Skip to main content
News

Baricitinib Outperforms Placebo in Patients With Inadequate Response to Methotrexate

Twice the patients with an inadequate response to methotrexate achieved American College of Rheumatology 20% (ACR20) response with baricitinib compared with placebo, according to a study published online in the journal Clinical and Experimental Rheumatology.

The phase 3, double-blind study looked at the efficacy and safety of baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in 290 patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate. Patients in China, Brazil, and Argentina were randomly assigned 4-mg baricitinib once daily or placebo. 

According to the study, 58.6% of patients who received baricitinib achieved ACR20 response after 12 weeks of treatment compared with 28.3% who received placebo.
_______________________________________________________________________________________
You may also like...

Rheumatic Regional Pain Syndromes Affect Many Close Relatives of Patients With RA
TKIs Associated With Respiratory Tract Infections
JAK Inhibitor Selection Should Be Guided by Comedications and Renal or Hepatic Impairment
_______________________________________________________________________________________

Participants who received baricitinib also had statistically significant improvements on the Health Assessment Questionnaire-Disability Index and the Disease Activity Score for 28-joint counts with high-sensitivity C-reactive protein measure, as well as in morning joint stiffness, worst tiredness, and worst joint pain scales compared with participants who received placebo at week 12.

Rates of treatment-emergent adverse events, such as infections, were higher among patients receiving baricitinib compared with placebo through week 24. Rates of serious adverse events, however, were similar.

“In patients with rheumatoid arthritis who had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo,” researchers concluded.

—Jolynn Tumolo

Reference

Li Z, Hu J, Bao C, et al. Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study [published online ahead of print, 2020 May 20]. Clin Exp Rheumatol. PMID:32452344